Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss.

Bimagrumab is a monoclonal antibody that targets activin type II receptors, blocks myostatin and related proteins: it promotes muscle growth and prevents muscle loss, while causing weight loss. It has been effective in sporadic inclusion body myositi…

Preview only. Read the full abstract at the source